CompletedNot Applicable

Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

China50 participantsStarted 2019-06-13

Plain-language summary

Choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV) is a common vision-threatening complication and often affects adults of working age. Intravitreal injection of any anti-vascular endothelial growth factor (VEGF) drugs would significantly suppress the activity of the CNV and finally improve the visual acuity. However, more than half of the patients would need one or more further injection for the recurrence or uncontrolled with 1+pro re nata (PRN) treatment within one year, and whether increasing the initial loading of intravitreal injection of anti-VEGF would be more efficacy for the controlling the PM-CNV remained unknown.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients who are aged ≥18 years, male or female
✓. Active choroidal neovascularization secondary to pathologic myopia
✓. high myopia (defined as spherical equivalent ≤-6.0 diopter, AL≥26mm)
✓. presence of posterior changes compatible with pathologic myopia
✓. presence of active leakage from CNV, and presence of intra-retinal or subretinal fluid or increase of central retinal thickness
✓. Presence of at least 1 of the following lesion types:
✓. subfoveal
✓. juxtafoveal with involvement of the central macular area

What they're measuring

BCVA change

Timeframe: 12 months

Trial details

NCT IDNCT03971162

SponsorZhongshan Ophthalmic Center, Sun Yat-sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-01

View on ClinicalTrials.gov More Myopic Choroidal Neovascularisation trials